Skip to main content

Table 4 Univariate analyses of overall survival in patients with PC

From: Relationship between S100A4 protein expression and pre-operative serum CA19.9 levels in pancreatic carcinoma and its prognostic significance

Clinical parameter Follow-up cases (n) Median survival (months) 1-year cumulative survival rate (%) HR(95%CI) P value
Differentiation      0.000
 High 29 12 51.7 4.351 (11.473–28.527)  
 Middle 65 13 56.9 0.501 (12.018–13.482)  
 Low 26 8 0 0.630 (6.766–9.234)  
TNM stage      0.000
 I 11 15 72.7 1.651 (11.763–18.237)  
 II 45 15 66.7 2.789 (11.534–22.466)  
 III 46 10 26.1 0.751 (8.529–11.471)  
 IV 18 8 11.1 1.061 (5.921–10.079)  
Distant metastasis      0.004
 Present 25 9 24 0.389 (8.238–9.762)  
 Absent 95 12 48.4 0.696 (10.636–13.364)  
Lymph node metastasis     0.000
 Present 61 10 29.5 0.554 (8.914–11.086)  
 Absent 59 13 57.6 1.280 (10.491–15.509)  
S100A4      0.000
 Positive 89 10 24.7 0.471 (9.077–10.923)  
 Negative 31 23 96.8 2.127 (19.831–28.169)  
Serum CA19.9 level      0.001
 ≥ 35 U/ml 107 11 39.3 0.517 (9.987–12.013)  
 < 35 U/ml 13 21 76.9 2.397 (17.303–26.697)  
S100A4/CA19.9      0.000
 S100A4(+)/CA19.9(+) 83 10 22.9 0.504(9.012–10.988)  
 S100A4(+)/CA19.9(−) 6 11 50.0 4.899(1.398–20.602)  
 S100A4(−)/CA19.9(+) 24 22 95.8 1.752(19.567–26.433)  
 S100A4(−)/CA19.9(−) 7 25 100.0   
  1. S100A4(+/−) positive/negative expression of S100A4, CA19.9(+/−) higher serum CA19.9 levels (≥ 35 U/mL)/normal CA19.9 level (< 35 U/ml)